Metronidazol Fresenius (Metronidazole)

Metronidazole is taken up by susceptible microorganisms where its nitro group is reduced to reactive radicals. These radicals damage DNA and inhibit nucleic acid synthesis, leading to cell death. The reduction process occurs preferentially in anaerobic environments, allowing selective targeting of anaerobic bacteria and protozoa while sparing most human cells.

The dosing regimen for Metronidazol Fresenius is determined by the prescribing clinician based on the specific infection, severity, patient weight, renal function, and other clinical factors. Healthcare professionals should refer to local guidelines and adjust the dose as needed for each individual patient.

Metronidazol Fresenius is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Metronidazole is excreted in breast milk; nursing mothers should discuss risks and benefits with their healthcare provider.

To order Metronidazol Fresenius, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if required), and assist with import documentation.

Metronidazol Fresenius belongs to the nitroimidazole class, which is highly effective against obligate anaerobes and certain protozoa. Compared with alternatives such as clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations, metronidazole offers a broad anaerobic spectrum, excellent tissue penetration, and a generally favorable safety profile, though resistance patterns and individual patient factors must guide selection.

Metronidazol Fresenius should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if the solution appears discolored or contains particles.

Metronidazol Fresenius is administered intravenously by a healthcare professional. The solution is typically diluted in an appropriate compatible IV fluid and infused over a period determined by the prescriber, based on the infection being treated and the patient’s clinical status.

Serious adverse reactions, although rare, include seizures, severe allergic responses such as anaphylaxis, hepatotoxicity, blood dyscrasias (e.g., neutropenia, thrombocytopenia), and severe skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should be monitored for any signs of these conditions, and treatment should be discontinued if they occur.

Metronidazol Fresenius is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. Caution is also advised for individuals with severe hepatic impairment, and the drug should be avoided in patients who cannot abstain from alcohol during treatment due to the risk of a disulfiram‑like reaction.